NASDAQ$HOLX

Hologic Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Hologic had a strong start to fiscal 2021, driven by Diagnostics division and strengthened Breast Health and Surgical businesses.

Hologic's Q1 2021 revenue reached $1.61 billion, an 89.3% increase year-over-year, driven by strong performance in the Diagnostics division and growth in Breast Health and Surgical businesses. The company reported GAAP diluted EPS of $2.50 and non-GAAP diluted EPS of $2.86.

  • Revenue increased by 89.3% to $1.61 billion, with constant currency increase of 86.5%.
  • Organic revenue increased by 107.0%, or 104.0% in constant currency.
  • Worldwide molecular diagnostics revenue increased 457.6% to $995.3 million.
  • Cash flow from operations was $650.0 million, leading to debt repayment and stock repurchases.

Headline financials

Total Revenue

$1.61B

Previous: $851M+89.3%
EPS (adj)

$2.86

Previous: $0.61+368.9%
GAAP Gross Margin

73.3%

No prior period
Non-GAAP Gross Margin

77.2%

No prior period
Non-GAAP Operating Margin

60.2%

No prior period
Non-GAAP Net Margin

46.6%

No prior period
Capital Expenditures

-$32.4M

Previous: -$11.4M-184.2%
Free Cash Flow

$618M

Previous: $103M+502.5%
Net Income

$653M

Previous: $386M+69.4%
Operating Income

$886M

Previous: $125M+609.5%
Gross Profit

$1.18B

Previous: $434M+172.1%
Cash & Equivalents

$869M

Previous: $382M+127.7%
Total Assets

$7.55B

Previous: $6.31B+19.6%
Stock-Based Comp

$18.6M

Previous: $18.1M+2.8%

Revenue & EPS history

Hologic · Revenue · Quarterly

$1.61B

Q1 2021+89.3%vs Q1 2020
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Hologic · $2.46B total across 3 segments · Q1 2021

  • Diagnostics
    $1.13B
  • Molecular Diagnostics
    $995M+457.6%
  • Breast Health
    $333M

Forward guidance

Hologic expects strong financial performance to continue in the second quarter of fiscal 2021.

Tailwinds

  • Revenue is expected to be between $1,500 million and $1,560 million.
  • Reported revenue increase is projected to be between 98.4% and 106.3%.
  • Constant currency revenue increase is expected to be between 93.9% and 101.9%.
  • Organic revenue increase is forecasted to be between 96.2% and 104.3%.
  • Non-GAAP EPS is expected to be between $2.56 and $2.68.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-0.5%

Avg return

Earnings day

+0.2%

Avg return

5 days after

-0.1%

Avg return

30 days after

49%

35 / 72 earnings

Positive

+12.3%

Q3 2020

Best reaction

-11.4%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026+0.0%-0.6%+0.7%
Q4 2025+0.1%+0.1%+0.9%
Q3 2025+2.8%+4.4%+3.3%
Q2 2025-5.6%-3.2%+8.5%
Q1 2025-10.1%-11.4%-11.3%
Q4 2024-4.3%-4.3%-6.6%
Q3 2024+4.9%+6.4%+2.2%
Q2 2024+0.3%-0.2%-3.3%
Q1 2024-2.7%-0.4%-1.1%
Q4 2023+5.7%+5.4%+0.1%
Q3 2023-5.1%-5.9%-5.4%
Q2 2023-2.4%-2.6%-8.3%
Q1 2023+3.8%+3.6%-1.1%
Q4 2022+10.8%+12.4%+13.8%
Q3 2022+1.0%+1.3%-3.4%
Q2 2022+1.2%+3.4%+9.8%
Q1 2022+4.0%+3.8%+2.4%
Q4 2021-3.3%-5.9%-0.3%
Q3 2021+2.3%+5.0%+9.7%
Q2 2021-9.1%-9.9%-13.4%
Q1 2021+1.7%+11.2%-3.3%
Q4 2020+6.6%-5.0%+1.7%
Q3 2020+12.3%+14.8%-2.8%
Q2 2020+2.9%+2.6%+8.9%
Q1 2020-0.7%-1.8%-13.7%
Q4 2019-4.0%+8.8%+10.3%
Q3 2019-1.3%-6.5%-4.1%
Q2 2019-0.1%+0.7%-5.1%
Q1 2019+0.6%-0.5%+8.6%
Q4 2018+4.9%+1.2%+3.7%
Q3 2018-3.5%-1.9%-7.5%
Q2 2018-6.9%-6.8%-3.9%
Q1 2018-6.7%-6.6%-2.2%
Q4 2017+0.4%+2.9%+8.1%
Q3 2017-9.3%-11.3%-12.5%
Q2 2017-4.3%-5.1%-2.0%
Q1 2017-2.6%-2.9%+1.8%
Q4 2016+4.3%+8.5%+6.3%
Q3 2016+3.9%+5.8%+5.3%
Q2 2016-10.0%
Q1 2016-9.2%
Q4 2015+0.6%
Q3 2015+8.6%
Q2 2015+2.1%
Q1 2015+5.1%
Q4 2014-1.7%
Q3 2014+2.1%
Q2 2014+8.1%
Q1 2014-5.9%
Q4 2013-6.9%
Q3 2013-0.2%
Q2 2013+0.1%
Q1 2013-4.1%
Q4 2012-0.3%
Q3 2012-0.4%
Q2 2012-11.4%
Q1 2012+5.2%
Q4 2011-4.0%
Q3 2011-3.9%
Q2 2011-0.6%
Q1 2011+0.0%
Q4 2010+1.2%
Q3 2010+1.2%
Q2 2010-2.6%
Q1 2009-2.8%
Q1 2010-1.1%
Q2 2009+2.9%
Q4 2007+2.9%
Q4 2009+2.9%
Q3 2009-3.0%
Q3 2008-3.0%
Q4 2008-3.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro